

**American Academy of Orthopaedic Surgeons**  
**Clinical Guideline**  
**on**  
**Prevention of Pulmonary Embolism in Patients**  
**Undergoing Total Hip or Knee Arthroplasty**

Adopted by the American Academy of Orthopaedic Surgeons  
Board of Directors  
May 2007

**DISCLAIMER**

This clinical guideline was developed by an AAOS physician volunteer Work Group and is provided as an educational tool based on an assessment of the current scientific and clinical information and accepted approaches to treatment. It is not intended to be a fixed protocol as some patients may require more or less treatment. Patient care and treatment should always be based on a clinician's independent medical judgment given the individual clinical circumstances.

## **AAOS Clinical Practice Guideline Copyright**

### **Disclaimer**

This Clinical Practice Guideline was developed by an AAOS physician volunteer Work Group based on a systematic review of the current scientific and clinical information and accepted approaches to treatment and/or diagnosis. This Clinical Practice Guideline is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Clinical patients may not necessarily be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician's independent medical judgment, given the individual patient's clinical circumstances.

### **Disclosure Requirement**

In accordance with AAOS policy, all individuals whose names appear as authors or contributors to Clinical Practice Guideline filed a disclosure statement as part of the submission process. All panel members provided full disclosure of potential conflicts of interest prior to voting on the recommendations contained within this Clinical Practice Guidelines.

### **Funding Source**

This Clinical Practice Guideline was funded exclusively by the American Academy of Orthopaedic Surgeons who received no funding from outside commercial sources to support the development of this statement.

### **FDA Clearance**

Some drugs or medical devices referenced or described in this Clinical Practice Guideline may not have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a specific use only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

### **Copyright**

All rights reserved. No part of this Clinical Practice Guideline may be reproduced, stored in a retrieval system, or transmitted, in any form, or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the AAOS.

Published 2007 by the American Academy of Orthopaedic Surgeons  
6300 North River Road  
Rosemont, IL 60018  
First Edition  
Copyright 2007  
by the American Academy of Orthopaedic Surgeons

**American Academy of Orthopaedic Surgeons Clinical Guideline**  
**on**  
**Prevention of Symptomatic Pulmonary Embolism in Patients**  
**Undergoing Total Hip or Knee Arthroplasty**

**Summary of Recommendations**

**The following recommendations are based on a systematic review of the literature and are evidence-based**

***Recommendation 3.3 Chemoprophylaxis of patients undergoing hip or knee replacement***

***Recommendation 3.3.1 Patients at standard risk of both PE and major bleeding*** should be considered for one of the chemoprophylactic agents evaluated in this guideline, including-in alphabetical order: **Aspirin, LMWH, synthetic pentasaccharides, and warfarin.** (Level III, Grade B (choice of prophylactic agent), Grade C (dosage and timing))

Note: The grade of recommendation was reduced from B to C for dosage and timing because of the lack of consistent evidence in the literature defining a clearly superior regime.

***Recommendation 3.3.2 Patients at elevated (above standard) risk of PE and at standard risk of major bleeding*** should be considered for one of the chemoprophylactic agents evaluated in this guideline, including-in alphabetical order: **LMWH, synthetic pentasaccharides, and warfarin.** (Level III, Grade B (choice of prophylactic agent), Grade C (dosage and timing)).

Note: The grade of recommendation was reduced from B to C for dosage and timing because of the lack of consistent evidence in the literature on risk stratification of patient populations.

***Recommendation 3.3.3 Patients at standard risk of PE and at elevated (above standard) risk of major bleeding*** should be considered for one of the chemoprophylactic agents evaluated in this guideline, including-in alphabetical order: **Aspirin, Warfarin, or none.** (Level III, Grade C)

Note: The grade of recommendation was reduced from B to C for dosage and timing because of the lack of consistent evidence in the literature on risk stratification of patient populations.

***Recommendation 3.3.4 Patients at elevated (above standard) risk of both PE and major bleeding*** should be considered for one of the chemoprophylactic agents evaluated in this guideline, including-in alphabetical order: **Aspirin, Warfarin, or none.** (Level III, Grade C)

Note: The grade of recommendation was reduced from B to C for dosage and timing because of the lack of consistent evidence in the literature on risk stratification of patient populations. No studies currently include patients at elevated risk of major bleeding and/or PE in study groups.

The following additional recommendations are based on the results of the objective AAOS Consensus Process in which the work group members participated.

***Recommendation 1.1*** All patients should be assessed pre-operatively for elevated risk (greater than standard risk) of pulmonary embolism. (Level III, Grade B)

***Recommendation 1.2*** All patients should be assessed pre-operatively for elevated risk (greater than standard risk) of major bleeding. (Level III, Grade C)

Note: Grade of Recommendation reduced because of lack of consistent evidence on risk stratification of patient populations.

***Recommendation 1.3*** Patients with known contraindications to anticoagulation should be considered for vena cava filter replacement. (Level V, Grade C)

***Recommendation 2.1*** Patients should be considered for intra-operative and/or immediate postoperative mechanical prophylaxis. (Level III, Grade B)

***Recommendation 2.2*** In consultation with the anesthesiologist, patients should be considered for regional anesthesia. (Level IV, Grade C)

***Recommendation 3.1*** Post-operatively, patients should be considered for continued mechanical prophylaxis until discharge to home. (Level IV, Grade C)

***Recommendation 3.2*** Post-operatively, patients should be mobilized as soon as feasible to the full extent of medical safety and comfort. (Level V, Grade C)

**Recommendation 3.4** Routine screening for DVT or PE post-operatively in asymptomatic patients is not recommended. (Level III, Grade B)

**Recommendation 4.1** Patients should be encouraged to progressively increase mobility after discharge to home. (Level V, Grade C)

**Recommendation 4.2** Patients should be educated about the common symptoms of deep venous thrombosis and pulmonary embolism. (Level V, Grade B)

Note: The level of evidence is level V, expert opinion, but the strength of recommendation is B rather than C because patient education is consistent with the minimal expected standard of care for today's medical practices.

Of the fourteen recommendations listed above, only recommendations 3.3.1, 3.3.2, 3.3.3 and 3.3.4 are based on the systematic review of the literature conducted between August 2006 and March 2007 by The Center for Clinical Evidence Synthesis at Tufts New England Medical Center. The other recommendations contained in this guideline are based on consensus development methods only.

# **American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty**

## **Overview**

### **Goals and Rationale**

This clinical guideline has been created to improve patient care by outlining the appropriate information gathering and decision making processes involved in managing the prevention of symptomatic pulmonary embolism (PE) in patients undergoing total hip or knee arthroplasty. This guideline has been created as an educational tool to guide orthopaedic surgeons and other clinicians who provide peri-operative care through a series of treatment decisions in an effort to improve the quality and efficiency of care.

This guideline should not be construed as including all proper methods of care or excluding methods of care reasonably directed to obtaining favorable results. The ultimate judgment regarding any specific procedure or treatment must be made in light of each patient's unique presentation and the needs and resources particular to the locality or institution.

### **Scope and Organization**

#### **Intended Users**

The intended users of this guideline are orthopaedic surgeons who perform total hip or knee replacement and other clinicians who provide peri-operative care to patients who have undergone either of the procedures.

#### **Patient Population**

The patient population for whom this guideline has been prepared includes all patients who will undergo total hip or knee replacement for arthropathies that are not related to acute traumatic injury. It was the intention of the Work Group that the guideline be applicable to as widely diverse a population as possible. The literature that was extracted has variable applicability because of the eligibility criteria that were used in assembling the study populations. In many studies high risk patients are excluded because of their potential for confounding the analysis of efficacy. Therefore the task of formulating a risk stratification strategy fell largely to the level of expert opinion of the convened Work Group.

## Burden of Disease

### Incidence, Etiology, and Risk Factors

Orthopaedic surgery has been identified as a uniformly high-risk event for venous thromboembolism. The most recent ACCP guideline states, “Without prophylaxis, the incidence of objectively confirmed, hospital-acquired DVT is approximately 10 to 40% among medical or general surgical patients and 40 to 60% following major orthopedic surgery”(1). Total hip and knee replacement are examples of commonly performed orthopaedic procedures in which a significant incidence of deep venous thrombosis (DVT) has been recorded. Because DVT has been widely accepted as a proxy measure for the risk of PE it has naturally been assumed that any improvements in DVT prevention would be proportionately accompanied by added protection against PE.(2) Although current appropriately powered clinical trials have demonstrated statistically significant differences in DVT rates among selected agents, as this guideline will demonstrate by way of a systematic literature review, the concurrently reported PE rates for all prophylactic modalities are not statistically different (see Appendix III). One explanation for this may be that studies with DVT as an end point are underpowered to demonstrate real differences in PE rates that may exist. Liereported a 60-day PE-related mortality rate of 0.37% in 67,548 total hip replacement patients from the Norwegian Arthroplasty Registry (1987-1989), concluded that given the low PE rates, it would require the randomization of 30,000 patients to demonstrate a 50% reduction in mortality between two competing agents (3). Needless to stay, the cost of such a study would be prohibitive. Another explanation may be that other risk factors and pathophysiological processes may control the development of PE, apart from the sheer presence of a DVT. In any case, the presumed direct pathophysiologic link between DVT and PE has not been proven by clinical observation, at least in the case of total hip and knee replacement. What then are the appropriate criteria for prescribing the safest and most effective thromboprophylactic regimens that will bring value to patients and to our financially stressed health care system?

PE following total hip or knee replacement is rare. In total hip replacement, the 90-day rate of non-fatal PE has been reported by Katz to be 0.93% in 58,521 Medicare patients who underwent primary total hip replacement with or without prophylaxis during 1995-1996 (4). Death following PE in total hip replacement is very rare, with a 90-day death rate reported by Howie in 44,785 patients in the Scottish Morbidity Record from 1992-2001 being 0.22%. Non-fatal and fatal PE following total knee replacement are even less common (5). SooHoo surveyed a California discharge database containing 222,684 patients who had undergone total knee replacement from 1991-2001. The 90-day non-fatal PE rate was reported as 0.41% (6). Howie reported a 0.15% rate of fatal PE in 27,000 total knee replacement patients in the Scottish Morbidity Record (5). In addition it has been shown that despite significant changes in venous thromboembolism prophylaxis and surgical techniques over the past 10 to 15 years, the rates of PE and PE-related mortality have been remarkably stable (3;5).

The occurrence of major bleeding complications following an elective total hip or knee replacement is potentially detrimental to patient outcomes, for example, resulting in chronic joint stiffness and infection. This systematic review found major bleeding episodes following total hip and knee replacement occurring with a frequency of 1% to 3%. Bleeding is a common cause of unplanned return to the operating room for evacuation of a hematoma, or, in the worst case,

removal of the implant because of infection. There is no contemporary study that adequately describes the incidence of major surgical bleeding in patients who have not received prophylaxis, but all reports of mechanical antithrombotic devices are noteworthy for an incidence of major bleeding of less than 1%. The literature is non-standardized with regard to identification and confirmation of major post-operative bleeding. There is significant variability in operationally defining a major bleed and the appropriate treatment options. The result has been a substantial likelihood of underestimating the bleeding risks. Moreover, studies that do report on bleeding-related complications do not have long-term follow-up that would link bleeding to the serious development of deep infection. Recent studies have demonstrated an important relationship between early post-operative wound hematoma and drainage and prosthetic joint infections (7;8). With the defined risk of surgical bleeding that may lead to more serious complications and compromised outcomes, and a historically low rate of life-threatening PE, the question may legitimately be asked, “Are the resources currently available to prevent serious thromboembolic complications of total hip and knee replacement being appropriately and cost-effectively utilized?”

### ***Relevant Issues***

The selection of an appropriate prophylactic regimen against PE in hip and knee replacement should be based on a balance between bleeding-related risks and medical adverse effects, on one hand, and the expected effectiveness in preventing symptomatic PEs, on the other. Using a regimen that has been shown to reduce the DVT rate does not necessarily imply that the risk-benefit ratio has been optimized. Therefore the optimal prophylactic regimen for a particular patient should reflect a clinical judgment regarding the relative risks of both major bleeding and symptomatic PE. An evidence-based stratification of the prophylactic regimens in terms of their risk of major bleeding would theoretically facilitate a more rational selection of prophylaxis based upon a more accurate risk-benefit profile. Eventually it may be possible to “customize” prophylaxis by better understanding of PE in various defined populations. The stratification of risk is currently difficult in light of the fact that all orthopaedic procedures are considered high risk for developing DVT. The more important task of risk stratification for PE and bleeding in total hip or knee replacement patients would require far more patients studied rigorously over a longer period of time than the current literature provides. Typically, randomized trials in this area exclude perceived “high risk” patients, who, by definition would need to be included in a study that is designed to scientifically prove the validity of a risk stratification methodology. Such studies should be conducted in a “real world” setting to achieve a more robust data set. In the absence of inclusive data it is very difficult to devise a sound clinical decision support process based purely on the results of randomized clinical trials. Alternatively, total joint registries offer the benefit of generalizability, realized by a more efficient and timely amalgamation of data taken from multiple surgeons and institutions. These data sets also deliver long-term follow-up that may link important risk factors with surgical outcomes.

## **Methods**

### **Process Overview**

A Work Group, with the assistance of an Evidence Review Team (ERT) from the Center for Clinical Evidence Synthesis at Tufts-New England Medical Center, completed a systematic

review of the relevant literature. Details of the systematic review process are provided below and in Appendix I; the results of the systematic review are presented in Appendix III. The Work Group included orthopaedic surgeons with clinical research experience. The members of the ERT were physician/clinical research methodologists with expertise in systematic review and guideline development. During the process of developing this document, the Work Group participated in numerous conference calls and a face-to-face meeting. Information from the systematic review was supplemented by additional literature suggested by the Work Group. The overall aim was to create guidelines and clinical performance measures through an evidence-based approach for the management of patients undergoing total hip or knee arthroplasty with the express purpose of preventing symptomatic PE. The primary key questions were addressed by a systematic review of the relevant literature. When available, high or moderately high quality evidence relevant to the primary key questions formed the basis for the development of evidence-based clinical practice guidelines. When only low quality or no evidence were available, guidelines were developed based on the consensus of expert opinion and the best available evidence.

The creation of the guidelines included many concurrent steps.

- Form the Work Group responsible for development of the guidelines
- Confer to discuss guideline development process, methods, and results
- Develop and refine primary key questions
- Define specific populations, interventions or predictors, comparator, and outcomes of interest, and other study eligibility criteria
- Create draft guideline statements and rationales
- Create and standardize quality and applicability assessment methods
- Create data extraction forms
- Develop literature search strategies and run searches
- Screen abstracts and retrieve full articles based on the predetermined eligibility criteria; screen and incorporate (if appropriate) additional literature suggested by the Work Group
- Extract data and perform critical appraisal of the literature
- Grade quality and applicability of each eligible study
- Tabulate data from articles into summary tables and perform analyses
- Perform meta-analyses (quantitative synthesis of data) when appropriate
- Grade the levels of evidence for each primary key question
- Write guideline recommendations and supporting rationale statements
- Grade the strength of the recommendations
- Write clinical performance measures

The Work Group participated in a series of conference calls for training in the guideline development process, topic discussion, and consensus development. During a meeting, the level of evidence for each recommendation was assigned and the strength of each of the recommendations was graded.

## **Creation of Panel**

The AAOS Guidelines Oversight Committee and the Evidence Based Practice Committee Chairpersons appointed the Chair of the Work Group and members with clinical domain expertise in hip and knee replacement surgical procedures, who were then, assisted by the

physician/clinical research methodologists with expertise in guideline creation from the ERT, contracted by the AAOS. The Work Group, with assistance from the ERT, refined and formulated the final four systematic review research questions using a well-established system (9).

The ERT developed specific screening criteria and literature search strategies, performed the literature search, screened abstracts and full-text articles, created forms and extracted relevant data from articles, tabulated and confirmed results, conducted statistical analyses, assisted with grading the strength of the evidence, and offered suggestions for guideline development. Throughout the process, they led discussions on systematic review, literature searches, data extraction, assessment of quality and applicability of articles, evidence synthesis, grading the quality of evidence and the strength of guideline recommendations, and the consensus development process for guideline creation. The ERT were the principal reviewers of the literature, and instructed and coordinated Work Group members in all steps of systematic review, critical literature appraisal, and guideline development. The Work Group reviewed in detail the results and conclusions of the ERT, and took the primary roles of writing the guidelines and rationale statements and grading the levels of evidence and the strength of the recommendations.

### **Consensus Development**

Voting on guideline recommendations and performance measures was conducted using a modification of the nominal group technique defined by AAOS, in which each work group member ranked a recommendation or performance measure on a scale ranging from 1 (“extremely appropriate”) to 9 (“extremely inappropriate”). Consensus was obtained if 8 of the 9 Work Group members ranked the recommendation or measure as 7, 8, or 9. When 2 or more Work Group members did not rank a measure in this range, three rounds of discussion and voting were held to resolve disagreements. If disagreements were not resolved after these rounds, no recommendation or performance measure was adopted.

## Work Group

Norman A. Johanson, MD- Chair  
Drexel University College of Medicine  
Department of Orthopaedic Surgery  
245 N 15th Street, Mail Stop 420  
Philadelphia, PA 19102-1192  
Email: [Norman.johanson@drexelmed.edu](mailto:Norman.johanson@drexelmed.edu)

Paul F Lachiewicz, MD (Hip Society Rep)  
University of North Carolina School of Medicine  
3151 Bioinformatics Bldg, CB 7055  
Chapel Hill, NC 27599-7055  
E-Mail: [paul\\_lachiewicz@med.unc.edu](mailto:paul_lachiewicz@med.unc.edu)

Jay R. Lieberman, MD  
Director, The Musculoskeletal Institute  
Chairman, Department of Orthopaedic Surgery  
University of Connecticut Health Center  
263 Farmington Ave.  
Farmington, CT 06030-5456  
E-Mail: [jlieberman@uchc.edu](mailto:jlieberman@uchc.edu)

Paul A. Lotke, MD (Knee Society Representative)  
510 Darby Rd  
Havertown, PA 19083  
E-Mail: [paul.lotke@uphs.upenn.edu](mailto:paul.lotke@uphs.upenn.edu)

Javed Parvizi, MD (AAHKS Representative)  
Rothman Institute  
925 Chestnut St-5th Fl  
Philadelphia, PA 19107  
E-Mail: [parvj@aol.com](mailto:parvj@aol.com)

Vincent Pellegrini, MD  
University of Maryland School of Medicine  
Department of Orthopaedics  
22 S Greene St, Ste S 11B  
Baltimore, MD 21201  
E-Mail: [vpellegrini@umoa.umm.edu](mailto:vpellegrini@umoa.umm.edu)

Theodore A. Stringer, MD (BOC Representative)  
3207 N Academy Blvd, Ste 103  
Colorado Springs, CO 80917-5117  
E-Mail: [tedstringr@aol.com](mailto:tedstringr@aol.com)

Paul Tornetta III, MD (OTA Representative)  
Boston Medical Center  
Department of Orthopedic Surgery  
850 Harrison Ave., Dowling 2 North  
Boston, MA 02118  
E-Mail: [ptornetta@pol.net](mailto:ptornetta@pol.net)

### **AAOS Staff:**

Robert H. Haralson III, MD, MBA  
Medical Director  
6300 N River Road  
Rosemont, IL 60018  
Email: [haralson@aaos.org](mailto:haralson@aaos.org)

Charles M. Turkelson, PhD  
Director of Research and Scientific Affairs  
6300 N River Road  
Rosemont, IL 60018  
Email: [turkelson@aaos.org](mailto:turkelson@aaos.org)

Janet L. Wies, MPH  
Clinical Guideline Manager  
6300 N River Road  
Rosemont, IL 60018  
Email: [wies@aaos.org](mailto:wies@aaos.org)

### **Panel Guest and Alternate Guidelines Oversight Chair:**

William C. Watters, III MD  
6624 Fannin #2600  
Houston, TX 77030  
Email: [spinedoc@pdq.net](mailto:spinedoc@pdq.net)

### **The Center for Clinical Evidence Synthesis (CCES), Tufts-New England Medical Center Staff**

750 Washington Street – NEMC #63  
Boston, MA 02111

Ethan Balk, MD, MPH  
Project Leader, Associate Director, CCES  
Email: [ebalk@tufts-nemc.org](mailto:ebalk@tufts-nemc.org)

Stanley Ip, MD  
Email: [sip@tufts-nemc.org](mailto:sip@tufts-nemc.org)

Gowri Raman, MD  
Email: [graman@tufts-nemc.org](mailto:graman@tufts-nemc.org)

May Adra, PharmD  
NEMC #420  
Email: [madra@tufts-nemc.org](mailto:madra@tufts-nemc.org)

Joseph Lau, MD  
Director, CCES  
Email: [jlau1@tufts-nemc.org](mailto:jlau1@tufts-nemc.org)

## Key Questions

The central guideline recommendations are based on the answers to four Key Questions. These questions were specified prior to conducting the literature searches and frame the scope of the guideline. Questions were constructed to specify the patients, interventions, comparisons, and outcomes of interest. The Key Questions addressed by these guidelines were:

- 1A. In patients having knee replacement surgery, what is the effect of prophylactic therapy (e.g., coumadin, low molecular weight heparin, aspirin, mechanical devices) compared with either no prophylaxis or placebo in preventing important clinical symptoms or events (e.g., shortness-of-breath, chest pain, arrhythmia, fatality, rehospitalization) secondary to pulmonary embolism?
- 1B. In patients having hip replacement surgery, what is the effect of prophylactic therapy (e.g., coumadin, low molecular weight heparin, aspirin, mechanical devices) compared with either no prophylaxis or placebo in preventing important clinical symptoms or events (e.g., shortness-of-breath, chest pain, arrhythmia, fatality, rehospitalization) secondary to pulmonary embolism?
- 2A. In studies of knee replacement surgery, how do these different prophylactic therapies compare among each other in preventing important clinical symptoms or events secondary to pulmonary embolism?
- 2B. In studies of hip replacement surgery, how do these different prophylactic therapies compare among each other in preventing important clinical symptoms or events secondary to pulmonary embolism?
3. What are risks of clinically important adverse events associated with these prophylactic therapies in patients having knee or hip replacement surgery?
- 4A. What is the risk of important clinical symptoms or events secondary to pulmonary embolism in patients who had knee replacement surgery, in whom no prophylactic therapies for the prevention of pulmonary embolism were prescribed?
- 4B. What is the risk of important clinical symptoms or events secondary to pulmonary embolism in patients who had hip replacement surgery, in whom no prophylactic therapies for the prevention of pulmonary embolism were prescribed?

## Systematic Review

A full description of the methods used and results of the systematic review and meta-analyses can be found at [www.aaos.org/research/guidelines/guide.asp](http://www.aaos.org/research/guidelines/guide.asp). Briefly, a formal process was used to determine study eligibility criteria and to identify studies. For Key Questions 1 to 3, the ERT included prospective studies that evaluated at least 100 patients receiving either aspirin, fondaparinux, low molecular weight heparin (LMWH), mechanical devices, warfarin, or any combination of these prophylaxis regimens after either hip or knee arthroplasty performed after 1995. It was the opinion of the Work Group that surgical techniques and post-operative management had changed substantially since the care provided prior to 1996. The consensus was reached to exclude these patients from the review.

In addition, randomized trials comparing at least two of the interventions with at least 10 patients in each arm were included. Outcomes of interest principally included symptomatic, clinically

documented PE, PE-related death, all-cause death, major bleeding, bleeding-related death, and rehospitalization due to venous thromboembolism or bleeding. Eligible studies were summarized by the ERT for the Work Group, which reviewed summary tables and the primary articles as needed. Event rates were combined using a variety of statistical techniques to ensure the robustness of the results due to the behaviors of the statistical methods at very low event rates. For Key Question 4, eligible studies included prospective or retrospective studies with at least 1000 patients who received either total hip or knee replacement after 1995, but did not receive any prophylaxis. However, no such studies were found. Studies were rated for methodological quality (good, fair, or poor) applicability to the population of interest (wide, moderate, narrow).

## **Summarizing Reviews and Selected Original Articles**

Work Group members summarized narrative reviews and citing original articles for topics that were outside the key questions addressed by the systematic review.

## **Rating the Quality of Evidence**

The quality of evidence was rated using an evidence hierarchy for each of four different study types; therapeutic, prognostic, diagnostic, and economic or decision modeling. These hierarchies are shown in Appendix II. These hierarchies were predefined by AAOS and appear on the AAOS website at [www2.aaos.org/aaos/archives/bulletin/feb03/fline1.htm](http://www2.aaos.org/aaos/archives/bulletin/feb03/fline1.htm).

## **Grading the Recommendations**

Each guideline recommendation was graded using the following system:

- A: Good evidence (Level I Studies with consistent finding) for recommending intervention.
- B: Fair evidence (Level II or III Studies with consistent findings) for recommending intervention.
- C: Poor quality evidence (Level IV or V) for recommending intervention.

## **Revision Plans**

Because of the high level of interest in this topic and the likelihood of rapidly emerging evidence, opinion, and practice, the guidelines will need to be revisited and revised in accordance with new, and we hope, higher quality evidence. It is anticipated that the guidelines will be revised in 2010.

# Guideline Recommendations

## Recommendation 1. Pre-operative Care

**1.1** All patients should be assessed pre-operatively for elevated risk (greater than standard risk) of pulmonary embolism. The following patients are examples of those considered to be at elevated risk:

- Hypercoagulable states
- Previous documented pulmonary embolism

**Level of Evidence: III**

**Grade of Recommendation: B**

**1.2** All patients should be assessed pre-operatively for elevated risk (greater than standard risk) of major bleeding. Patients with the following conditions are examples of those considered to be at elevated risk:

- History of a bleeding disorder
- History of recent gastrointestinal bleed
- History of recent hemorrhagic stroke

**Level of Evidence: III**

**Grade of Recommendation: C**

**Note: This Grade of Recommendation was reduced from B to C because of the lack of consistent evidence in the literature on risk stratification of patient populations.**

**1.3** Patients with known contraindications to anticoagulation should be considered for vena cava filter placement.

**Level of Evidence: V**

**Grade of Recommendation: C**

## Rationales

### Recommendation 1.1

The risk of PE, however, differs among different patients; however, there is currently no satisfactory evidence-based risk stratification system. There have been studies suggesting that the risk of PE is elevated in patients with previous history of cancer, thromboembolism, hypercoagulable states such as polycythemia, spinal cord injury patients, and multi-trauma patients(10-12). It is also plausible that some patients may have genetic predisposition for development of PE(13;14). Currently no specific laboratory test can reliably identify patients at elevated risk of PE. Therefore, careful history taking and physical examination in combination with clinical judgment, which integrates knowledge of specific risk factors with the patient's clinical status is the cornerstone of PE risk management for patients undergoing hip or knee replacement.

The identification of patients at elevated risk for PE is important in the selection process of appropriate thromboprophylactic regimens (see Recommendation 3.3).

### Recommendation 1.2

The selection of a thromboprophylactic regimen should aim for a balance between efficacy and safety. All chemoprophylaxis agents, by virtue of their action, are associated with bleeding. Some agents may result in a higher incidence of bleeding following total joint arthroplasty (15); although the differences in bleeding rates with the currently used agents are unclear (see Guideline 3.3) (16-19). Patients on aspirin or mechanical prophylaxis alone, on the other hand, may have lower bleeding rates (15;20-22). Not only might the bleeding potential of different prophylactic agents vary, there may also be varying bleeding tendencies among individuals that may affect the bleeding risk with surgery(23). The intention of this recommendation is to identify patients who may be at elevated risk of major bleeding after hip or knee replacement. The type of prophylactic agent, the duration of prophylaxis, and the intensity of anticoagulation needs to be modulated based on the perceived bleeding risk in an individual patient. Some factors that may place a patient at an elevated risk of bleeding include a previous history of uncontrolled bleeding, and a known coagulation factor deficiency, a recent history of gastrointestinal bleeding, and recent hemorrhagic stroke. This recommendation highlights the central importance of careful history taking, and physical examination for the purpose of risk stratification for bleeding. Although routine serological tests to screen patients for potential bleeding problems are not indicated, they may be useful in patients where there is a high level of suspicion of a predisposition for bleeding.

### **Recommendation 1.3**

A vena cava filter may reduce the risk of PE in a non-anticoagulated patient(24). The assumed ability of a filter to stop emboli originating in the lower extremities underlies the expected clinical usefulness of filters in selected total hip and knee patients. The very low level of evidence and strength of recommendation reflect the poor evidence base behind this decision-making process. The need for a filter is most commonly encountered when there is elevated pre-operative risk of PE and a known contraindication for chemoprophylaxis, or if chemoprophylaxis becomes contraindicated in an elevated risk patient during the postoperative course. Similarly, if a patient with a known contraindication to chemoprophylaxis changes from standard to elevated PE risk in the postoperative period, a vena cava filter may be considered. Finally, in patients thought to be at elevated risk of major bleeding who develop symptomatic post-operative PE, a filter should be considered.

## ***Recommendation 2: Intra-operative Care***

**2.1** Patients should be considered for intra-operative and/or immediate postoperative mechanical prophylaxis.

**Level of Evidence: III**

**Grade of Recommendation: B**

**2.2** In consultation with the anesthesiologist, patients should be considered for regional anesthesia.

**Level of Evidence: IV**

**Grade of Recommendation: C**

### **Rationales**

#### **Recommendation 2.1**

Thrombogenesis activation begins during total hip arthroplasty through a variety of mechanisms. These include venous stasis due to anesthesia, immobilization, intimal injury (due to kinking of the femoral vein with dislocation of the hip and femoral canal preparation) and activation of the clotting cascade (by a variety of mechanisms) (25;26). Mechanical venous compression ameliorates some of the factors involved in thrombogenesis and therefore should be considered intraoperatively, if practical, and there are no contraindications to use of the device (27;28). For total hip arthroplasty, mechanical prophylaxis can easily be used on the nonoperative limb, and there are sterile thigh-calf and calf-only pneumatic devices that can be used on the operative limb (27-29). In observational studies, the use of these devices (usually in combination with regional anesthesia and aspirin chemoprophylaxis) have been shown to result in a low rate of symptomatic PE (25;28). Alternatively, these pneumatic devices may be placed on the lower extremities in the recovery room after the procedure is completed (30). There are a variety of mechanical devices available, including thigh-calf, calf-only, and foot pumps (31). There are no prospective, randomized studies comparing the efficacy of these devices in the prevention of symptomatic PE.

The activation of thrombogenesis in total knee arthroplasty patients has been less well studied.. Intraoperative mechanical compression can be used on the nonoperative limb, but there is no effective sterile device for use on the operative limb, especially if a tourniquet is used. Most studies begin use of a mechanical device on the operative limb postoperatively in the recovery room (32-35).

#### **Recommendation 2.2**

Regional anesthesia (spinal, epidural or hypotensive epidural with cardiac monitoring) has been recommended over general endotracheal anesthesia for total hip and total knee arthroplasty patients (25;26;36;37). Regional anesthesia has been shown to decrease venous flow less and result in fewer pulmonary complications. However, there is only circumstantial evidence that regional anesthesia, as part of a multimodal prophylaxis protocol, reduces the prevalence of symptomatic and fatal PE (27;28;36).

The choice of anesthetic technique for these patients is based on multiple factors, including thromboembolism prophylaxis. There should be close consultation between the surgeon and the anesthesiologist for the anesthetic technique.

### **Recommendation 3: Post-operative/Inpatient Care**

3.1 Post-operatively, patients should be considered for continued mechanical prophylaxis until discharge to home.

**Level of Evidence: IV**

**Grade of Recommendation: C**

3.2 Post-operatively, patients should be mobilized as soon as feasible to the full extent of medical safety and comfort.

**Level of Evidence: V**

**Grade of Recommendation: C**

3.3 Chemoprophylaxis of patients undergoing hip or knee replacement

3.3.1 **Patients at standard risk of both PE and major bleeding** should be considered for one of the chemoprophylactic agents evaluated in this guideline, including (*in alphabetical order*):

a. Aspirin, 325 mg 2x/day (reduce to 81 mg 1x/day if gastrointestinal symptoms develop), starting the day of surgery, for 6 weeks.

b. LMWH, dose per package insert, starting 12-24 hours post-operatively (or after an indwelling epidural catheter has been removed), for 7-12 days (N.B., the LMWHs have not been sufficiently evaluated for longer periods to allow recommendation beyond this period).

c. Synthetic pentasaccharides, dose per package insert, starting 12-24 hours post-operatively (or after an indwelling epidural catheter has been removed), for 7-12 days (N.B., the synthetic pentasaccharides have not been sufficiently evaluated for longer periods to allow recommendation beyond this period).

d. Warfarin, with an INR goal of  $\leq 2.0$ , starting either the night before or the night after surgery, for 2-6 weeks.

**Level of Evidence: III**

**Grade of Recommendation: B (choice of prophylactic agent), C (dosage and timing)**

**Note: Note: The Grade of Recommendation was reduced from B to C for dosage and timing because of the lack of consistent evidence in the literature defining a clearly superior regime.**

3.3.2 **Patients at elevated (above standard) risk of PE and at standard risk of major bleeding** should be considered for one of the following chemoprophylactic agents (*in alphabetical order*):

a. LMWH, dose per package insert, starting 12-24 hours post-operatively (or after an indwelling epidural catheter has been removed), for 7-12 days (N.B., the LMWHs have not been sufficiently evaluated for longer periods to allow recommendation beyond this period).

b. Synthetic pentasaccharides, dose per package insert, starting 12-24 hours post-operatively (or after an indwelling epidural catheter has been removed), for 7-12

days (N.B., the synthetic pentasaccharides have not been sufficiently evaluated for longer periods to allow recommendation beyond this period).

c. Warfarin, with an INR goal of  $\leq 2.0$ , starting either the night before or the night after surgery, for 2-6 weeks.

**Level of Evidence: III**

**Grade of Recommendation: B (choice of prophylactic agent), C (dosage and timing)**

**Note: Note: The Grade of Recommendation was reduced from B to C for dosage and timing because of the lack of consistent evidence in the literature on risk stratification of patient populations. No studies currently include patients at elevated risk of major bleeding in study groups.**

**3.3.3 Patients at standard risk of PE and at elevated (above standard) risk of major bleeding** should be considered for one of the following chemoprophylactic agents (*in alphabetical order*):

a. Aspirin, 325 mg 2x/day (reduce to 81 mg 1x/day if gastrointestinal symptoms develop), starting the day of surgery, for 6 weeks.

b. Warfarin, with an INR goal of  $\leq 2.0$ , starting either the night before or the night after surgery, for 2-6 weeks.

c. None

**Level of Evidence: III**

**Grade of Recommendation: C**

**Note: This Grade of Recommendation was reduced from B to C because of the lack of consistent evidence in the literature on risk stratification of patient populations. No studies currently include patients at elevated risk of major bleeding in study groups.**

**3.3.4 Patients at elevated (above standard) risk of both PE and major bleeding** should be considered for one of the following chemoprophylactic agents (*in alphabetical order*):

a. Aspirin, 325 mg 2x/day (reduce to 81 mg 1x/day if gastrointestinal symptoms develop), starting the day of surgery, for 6 weeks.

b. Warfarin, with an INR goal of  $\leq 2.0$ , starting either the night before or the night after surgery, for 2-6 weeks.

c. None

**Level of Evidence: III**

**Grade of Recommendation: C**

**Note: This Grade of Recommendation was reduced from B to C because of the lack of consistent evidence in the literature on risk stratification of patient populations. No studies currently include patients at elevated risk of major bleeding and PE in study groups.**

3.4 Routine screening for DVT or PE post-operatively in asymptomatic patients is not recommended.

**Level of Evidence: III**

**Grade of Recommendation: B**

## **Rationales**

### **Recommendation 3.1**

Unless contraindicated, mechanical compression should be utilized for both total hip(25;27-30;34) and knee arthroplasty (32-35). for patients in the recovery room and during the hospital stay . The optimal number of hours daily that mechanical compression should be used is unknown. A team approach involving surgeons, nurses, aides and therapists is required to optimize the amount of time the devices are on the patients' limbs. Many patients are transferred to "same site" rehabilitation floors or hospital services early postoperatively. It is recommended that mechanical prophylaxis continue at these locations if practical.

One prospective randomized study showed that rapid-inflation, asymmetric calf compression was superior to circumferential calf compression in total knee patients (32). For total hip patients, the postoperative devices studied included thigh-calf compression (27;28), rapid-inflation calf (30;34), other calf compression and foot pumps, usually part of a multimodal prophylaxis protocol. Patient preferences and comfort should be taken into account, when feasible. One study reported a high prevalence of patient intolerance and discontinuation of foot pumps postoperatively after total hip arthroplasty (21).

### **Recommendation 3.2**

At a minimum, patients should be taught to actively dorsiflex and plantar flex the ankle and toes. This exercise should be performed in sets of 10 to 20 every half hour when the patient is awake. A plan for pain management that allows control for the patient to be out of bed and subsequently ambulate should be in place prior to surgery. All patients should be out of bed to a sitting chair several times a day for several hours at a time to encourage deep breathing and avoid recumbency. All efforts should be made to have the patient stand and ambulate within the restrictions placed by the operative surgeon. Practices should be in place to ensure that appropriate physical therapy, ambulatory assistance, and support are provided by the first postoperative day. Patients who are treated with epidural catheters postoperatively should also be out of bed to chair as soon as feasible. Standing and ambulation should begin for these patients when they are physically capable of it. During hospitalization, when patients are not ambulating mechanical prophylaxis should remain in place at all times, even when the patient is out of bed.

### **Recommendation 3.3**


The studies that were systematically reviewed for this guideline primarily addressed Recommendation 3.3. A full description of the results of the systematic review can be found at [www.aaos.org/research/guidelines/guide.asp](http://www.aaos.org/research/guidelines/guide.asp). Briefly, 42 studies met eligibility criteria, of which 23 included patients who had knee arthroplasty and 25 included patients who had hip arthroplasty. Across the studies, outcomes were reported for 11,665 patients who received knee arthroplasty and for 16,304 patients who received hip arthroplasty. None of the studies was deemed to be of Good quality regarding the outcomes of interest; 23 studies were graded Fair

quality; and 19 were graded Poor quality. Two studies had Wide applicability for pulmonary embolism-related outcomes, 21 had Moderate applicability and 18 had Narrow applicability for pulmonary embolism outcomes. The studies were highly heterogeneous regarding specific intervention, dose or intensity of intervention, start time and duration of intervention, follow-up time, co-treatments used, eligibility criteria, inclusion of patients receiving revision or bilateral surgery, surgical and anesthetic techniques.

There were major limitations to the body of evidence for estimating and comparing PE, death, and major bleeding rates. These included large clinical heterogeneity in the interventions, other related procedures and cointerventions, doses, study populations, follow-up times, and in the case of major bleeding, definitions. In addition, none of the studies was designed to investigate PE as a primary outcome. Reporting of PE-related events was frequently incomplete and vague. Commonly, it was not clear how many patients were evaluated for each outcome. The numbers of patients within each study were inadequate to properly estimate the event rates of interest for these guidelines. Because the event rates were frequently either zero or close to zero, combining data across studies could not provide robust estimates of event rates across studies. All evaluations were based on indirect comparisons across different arms (cohorts) of different studies.

The available evidence shows no statistically significant differences among the interventions in rates of pulmonary embolism, pulmonary embolism-related death, total death, major bleeding, bleeding-related death, or rehospitalization (**Figures 1-4**). However, given the rarity of these events, the total number of patients in the studies remains too small to adequately evaluate possible differences among the interventions. This lack of adequate evidence holds true for the broader comparison of systemic interventions (fondaparinux, LMWH, and warfarin) and mechanical devices or aspirin alone. Except to note that major bleeding was very rare among patients receiving aspirin or mechanical devices alone (1 case in 697, or 0.14%, exact 95% CI 0.03-0.8%) compared to those who received systemic interventions (random effects model summary estimate 1.8%, 95% CI 1.4-2.5%). Because of the limitations and the overall relatively small number of patients evaluated (given the rarity of pulmonary embolism after arthroplasty), at best rough estimates of event rates can be surmised from the evaluated evidence.

**Figure 1.** Summary pulmonary embolism, pulmonary embolism death, and total death rates for patients after hip arthroplasty receiving different prophylaxis regimens.



- = median rate among studies (only determined if  $\geq 3$  cohorts of patients)
- = simple average (total n/total N) and “exact” estimate of confidence interval of that average
- ▲-- = random effects estimate and confidence interval using Bayesian methodology
- = random effects estimate and confidence interval using logit of proportions methodology

Dotted vertical lines represent 0.2% increments.

Where there are ranges of total n's (events), one or more studies were unclear as to the total number of events (eg, whether PE's were confirmed or not, whether deaths were due to confirmed PE or not). Multiple medians or averages represent the range of estimates.

All systemic = LMWH + warfarin + fondaparinux studies combined (in addition to studies that combined these interventions).

LMWH = LMWH alone and combination LMWH & mechanical; Warfarin = warfarin alone and combination warfarin & mechanical.


Mechanical / Aspirin = Either mechanical alone, aspirin alone, or mechanical and aspirin

Aspirin= aspirin and combination aspirin and mechanical


These approaches do not adequately account for the heterogeneity of interventions, follow-up duration, quality, applicability, etc.

These analyses do not include studies that excluded events that occurred in-hospital.


**Figure 2.** Summary pulmonary embolism, pulmonary embolism death, and total death rates for patients after knee arthroplasty receiving different prophylaxis regimens.



**Figure 3.** Major bleeding and death from bleeding rates for patients after hip arthroplasty receiving different prophylaxis regimens.



**Figure 4.** Major bleeding and death from bleeding rates for patients after hip arthroplasty receiving different prophylaxis regimens.



### **Recommendation 3.3.1**

Patients with standard risk of PE and standard risk of major bleeding represent the majority of total joint replacement patients. As noted in the introduction to this guideline orthopaedic surgery carries with it a higher level of risk for thromboembolic complications than for general surgical or medical patients. Therefore the term “standard” should be understood as a relative term specifically for hip and knee replacement. Since the incidence rates of symptomatic PE are low, it is not possible to make definitive recommendations on the occurrence of PE alone. In order to determine differences in current chemoprophylactic regimens, we would need at least 25,000 and 150,000 patients, respectively (calculated using a relative risk of 0.5 for the efficacy of prophylaxis). These low incidence rates of PE and fatal PE mean that we must look more closely at the opposite side of the risk equation and fully assess the adverse effects (primarily bleeding) that result from our recommendations.

The bleeding risk from chemoprophylactic agents may rise with increased effectiveness in reducing DVT (15). The incidence of major bleeding is less than 1% in patients without chemoprophylaxis and may be as high as about 3 to 5% in patients given chemoprophylactic agents (38). Precise estimates of the true risk of bleeding are difficult to obtain since the definitions of major bleeds vary among different studies. In general, the definitions of a major bleed include; life threatening, intraocular, or intracerebral bleeds, or a bleed requiring more than a specified number of transfusions. Furthermore, most of the prospective data from drug comparison studies utilize selected populations, which exclude patients with prior gastrointestinal bleeds and noncompliant or frail patients. Also patients may not have been included within the major bleed definitions if they had bleeding events that did not immediately affect surgical outcomes. In general, clinical outcomes in patients with a defined major bleed or in the spectrum of patients with lesser bleeding have not been well studied.

The present recommendations reflect the Work Group’s concerns about increased bleeding associated with the use of chemoprophylactic agents without a demonstrated reduction in PE. The duration for the administration of chemoprophylactic agents has not been clearly established. The older literature notes that most postoperative PEs occurred within the first 6 week (5;39-42). Therefore, many regimens were established to conform to that experience. Some reports on the heparin like drugs, that shows it is not necessary to prolong the administration beyond the first 8 to 12 days (43). The Work Group’s recommendations reflect these practices.

Combinations of agents may also be considered, such as a short course of a LMWH followed by aspirin. However, there is no definitive evidence that demonstrates a reduction in PE using any of these regimens.

Recommendation 3.2, which recommends that patients should be mobilized rapidly after surgery unless contraindicated, should be viewed as universally applicable, regardless of choice of chemical chemoprophylaxis. Mechanical devices have no inherent bleeding risk; however, their effectiveness in reducing the incidence of PE has not been definitively demonstrated. Therefore, they remain an adjunct in the armamentarium for prophylaxis unless there is a contraindication for chemoprophylaxis, in which case they become the primary means of prevention.

### **Recommendation 3.3.2**

Warfarin (INR  $\leq$  2.0), LMWH, or a synthetic pentasaccharide are recommended as chemoprophylaxis for patients known or suspected to be at increased risk of PE after total hip or knee arthroplasty. In this clinical setting, the customary risk-benefit balance between therapeutic anticoagulation and bleeding risk is tipped in favor of the most effective prophylaxis while acknowledging a potentially higher bleeding risk as a tradeoff for optimal efficacy in prevention of PE.

The data presented in Figures 1 and 2 do not demonstrate differentiation of effectiveness among any of the chemoprophylactic agents in the prevention of PE. This is in clear contrast to the results of DVT oriented studies, where there is evidence to support distinctions. For example, the efficacy in prevention of DVT has been shown, in declining order, for the synthetic pentasaccharide (fondaparinux), LMWH (enoxaparin, dalteparin) (16;44-46), and low intensity warfarin (INR 2.0) (47).

Although the incidence of major bleeding after hip arthroplasty appears to be higher than knee arthroplasty (Figures 3 and 4) the clinical tolerance for major bleeding may be less after knee arthroplasty owing to the more superficial nature of the knee and the tenuous character of its soft tissue envelope. Therefore, a higher level of concern for post-operative bleeding in total knee replacement is prevalent among most surgeons in light of a theoretically higher potential for a bleed to compromise the clinical outcome.

In addition to the use of chemoprophylactic agents it is prudent to employ other adjunctive measures as outlined in Recommendations 2.1, 2.2, and 3.1.

### **Recommendation 3.3.3**

Patients that are at standard risk of PE but at an elevated risk of major bleeding are relatively uncommon. Examples of this include thrombocytopenia, bone marrow suppression, known hemophilia or other defined coagulation defects, recent radiation, or chemotherapy. The management of these patients should be individualized (perhaps in association with a hematologist). The first priority is to correct the clotting defect, if possible, prior to surgery, using transfusions of clotting factors, platelets, or frozen plasma. The use of a chemoprophylactic agent in a patient with a known diminished ability to clot must be considered judiciously, as there is currently no evidence base to assist in this decision.

In addition to the use of chemoprophylactic agents it is prudent to employ other adjunctive measures as outlined in Recommendations 2.1, 2.2, and 3.1.

### **Recommendation 3.3.4**

In the setting of elevated risk of both PE and major bleeding (above standard risk), the selection of the most appropriate prophylactic regimen is dependent on the clinical judgment of the surgeon and medical consultants. The final judgment is the result of integrating the knowledge of the severity of existent risk factors for PE and bleeding with the patient's current status.

Although the recommendations 3.3.3 and 3.3.4 regarding chemoprophylaxis contain identical agents, the range of options (from warfarin to no chemoprophylaxis) is wide. Particularly for patients at elevated risk of both PE and major bleeding, it is very important that the physician has as accurate an assessment as possible of the actual likelihood of a life-threatening PE. Aspirin, with its attendant very low risk of bleeding and warfarin, which can be dosed to lower INRs in

high-risk bleeding situations are the agents recommended if chemoprophylaxis is deemed necessary.

In addition to the use of chemoprophylactic agents it is prudent to employ other adjunctive measures as outlined in Recommendations 2.1, 2.2, and 3.1.

#### **Recommendation 3.4**

Specific recommendation is made against routine surveillance for venous thromboembolism after total hip or knee arthroplasty. There is neither a sufficiently sensitive noninvasive screening tool nor a clearly established period of risk for venous thromboembolism as to make routine screening reliably predictive or cost-effective in preventing PE.

The premise that routine screening is an effective strategy to prevent PE is predicated upon the hypothesis that secondary prophylaxis, namely prevention of propagation and embolization of existing thrombi, is a valid approach to reducing the incidence of PE. One study of over 3,000 patients with 6 month follow-up of readmission for symptomatic proximal DVT or PE demonstrated a readmission rate in patients discharged without continued anticoagulation on the basis of negative screening contrast venography nearly 8 times greater than patients who received 6 weeks of warfarin based on a positive screening venogram or empiric continuation of prophylaxis (48;49).

Other imaging modalities have been suggested for routine screening. Duplex ultrasound is highly operator dependent, test performance is variable from institution to institution, and the test is not sensitive to thrombus identification distal to level of the adductor canal and in the pelvis.

Magnetic resonance venography has been shown to be sensitive in imaging asymptomatic pelvic thrombi but remains costly and cumbersome to repeat on a regular basis.

Routine screening by genetic predisposition or identification of a single serum clotting factor has yet to demonstrate a strong correlation with venous thromboembolic disease after total hip or knee arthroplasty.

## ***Recommendation 4: Discharge to Home***

4.1 Patients should be encouraged to progressively increase mobility after discharge to home.

**Level of Evidence: V**

**Grade of Recommendation: C**

4.2 Patients should be educated about the common symptoms of deep venous thrombosis and pulmonary embolism.

**Level of Evidence: V**

**Grade of Recommendation: B**

Note: The level of evidence is level V, expert opinion, but the strength of recommendation was increased from C to B because patient education is consistent with the minimal expected standard of care for today's medical practices.

### **Rationales**

#### **Recommendations 4.1 and 4.2**

During post-operative hospitalization, the team caring for the patient, should collaborate with physical therapy, occupational therapy and discharge planning to extend hospital program to home environment. The team should stress appropriate range of motion, appropriate conditioning programs, and encouraging the patients to avoid prolonged immobility.

All patients should be educated regarding common symptoms of DVT and PE. DVT symptoms are usually localized to site and include: pain, swelling, tenderness and redness or discoloration of skin. PE symptoms include: shortness of breath, rapid pulse, sweating, feeling of apprehension, chest pains worsening with deep breath, coughing up blood, decreased blood pressure and light headedness.

These recommendations are an extension of the AAOS concept of patient-centered care encouraging patient education as part of the surgical process. The presumption is that patient participation and education will enhance awareness, improve outcomes and potentially diminish the risk associated with the procedure specifically the potential for PE-related morbidity and mortality.

### **Future Research**

Appropriately powered studies to detect the superiority of any preventive strategy for PE would be far more costly than for DVT. Consequently DVT, which occurs much more frequently, and seems to occur with a wider variability among treatment groups is a more attractive proxy measure. But the reduction of DVT does not appear to have a significant effect on the PE rate, and this calls into question the long assumed epidemiologic if not pathophysiologic link between the two processes. Additional research, which better describes this relationship, would be helpful.

Post-operative bleeding in and around the surgical wound is an example of a complication, which may be directly caused by prophylaxis. In contrast to an asymptomatic DVT a post-operative bleed may lead to even more serious problems that significantly impact the surgical outcome. In this sense the expected benefit of prevention of one type of surgical complication may be overshadowed by the increased risk of another. The incidence of major post-operative

bleeding should be addressed in a more uniform and standardized fashion to facilitate a more reliable comparison of different studies, and pooling of the results. The functional outcomes in patients with major bleeds should be followed in studies that are concerned primarily with thrombo-embolic events in order to fairly estimate the costs of treatment complications in comparison with those of fatal and non-fatal PE.

The issue of PE risk stratification in the pre-operative assessment of total hip and knee replacement patients is very important. By developing an evidence-based risk adjustment system it will be possible to utilize a more cost-effective individualized prophylactic strategy. Future research should be directed at the assessment of the incidence of PE following hip or knee replacement in large unselected populations where the potential risk factors are reliably documented. Large databases such as Medicare and those administered by states may provide some assistance, but currently do not include enough specific risk stratification and outcome variables. Hip and knee replacement registries present real opportunities to enhance the quality and applicability of the data. The AAOS has demonstrated a commitment to oversee the development of a national total joint registry which would facilitate an efficient and timely approach to preventing PE and post-operative bleeding complications. Successful implementation of this strategy would undoubtedly improve the quality of care for our patients and deliver value to the health care system.

## Conclusion

There were major limitations to the body of evidence, including large clinical heterogeneity in the interventions, other related procedures and cointerventions, doses, study populations, follow-up times, and in the case of major bleeding, definitions. In addition, none of the studies was designed to investigate PE as a primary outcome. Reporting of PE-related events was frequently incomplete and vague. Commonly, it was not clear how many patients were evaluated for each outcome. Overall, the numbers of patients within each study were inadequate to properly estimate the event rates of interest. Because the event rates were frequently either zero or close to zero, combining data across studies had limitations. We investigated 4 different methods of combining rates, but relied primarily on the simple pooled average (sum of events over sum of patients) as this method appeared to provide the most logical estimates, though narrow confidence intervals. Even if these limitations could have been better overcome, the evidence would still be very limited due to the near lack of direct comparisons within studies. Thus, all evaluations were based on indirect comparisons across different arms (cohorts) of different studies, a less reliable analysis than direct comparisons (e.g., randomized trials).

It is also important to note that the number of studies and patients evaluated were restricted by several decisions made regarding the eligibility criteria, including restriction to prospective studies (greatly reducing the number of patients evaluated, but avoiding the numerous biases and lack of pre-defined interventions of retrospective studies), study size restrictions (which greatly reduced the number of studies, but did not greatly reduce the number of subjects or events), and restriction to patients operated on since 1996. A large number of studies were not included because of this last restriction. However, the consensus among the Work Group was that surgical techniques and post-operative care have changed sufficiently since 1996. They agreed that estimates of PE and bleeding rates from older studies would not be accurate for contemporary patients. It was acknowledged though, that the specific choice of 1996 was somewhat arbitrary.

The available evidence shows no differences among the interventions in rates of PE, PE-related death, total death, major bleeding, bleeding-related death, or rehospitalization. This lack of adequate evidence holds true for the broader comparison of systemic interventions (fondaparinux, LMWH, and warfarin) and mechanical devices or aspirin alone. Except to note that major bleeding was very rare among patients receiving aspirin or mechanical devices alone (1 case in 697, or 0.14%, exact 95% CI 0.03-0.8%) compared to those who received systemic interventions (random effects model summary estimate 1.8%, 95% CI 1.4-2.5%). Because of the limitations and the overall relatively small number of patients evaluated (given the rarity of PE after arthroplasty), only approximate estimates of event rates can be surmised from the evaluated evidence.

## References

- (1) Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.[see comment]. [Review] [794 refs]. *Chest* 2004 Sep;126(3 Suppl):338S-400S.
- (2) Warwick D. New concepts in orthopaedic thromboprophylaxis.[see comment]. [Review] [31 refs]. *Journal of Bone & Joint Surgery - British Volume* 2004 Aug;86(6):788-92.
- (3) Lie SA, Engesaeter LB, Havelin LI, Furnes O, Vollset SE. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. *Acta Orthopaedica Scandinavica* 2002 Aug;73(4):392-9.
- (4) Katz JN, Losina E, Barrett J, Phillips CB, Mahomed NN, Lew RA, et al. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States medicare population.[see comment]. *Journal of Bone & Joint Surgery - American Volume* 2001 Nov;83(A(11)):1622-9.
- (5) Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. *Journal of Bone & Joint Surgery - British Volume* 2005 Dec;87(12):1675-80.
- (6) SooHoo NF, Lieberman JR, Ko CY, Zingmond DS. Factors predicting complication rates following total knee replacement. *Journal of Bone & Joint Surgery - American Volume* 2006 Mar;88(3):480-5.
- (7) Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, Di Cesare PE. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. *Journal of Bone & Joint Surgery - American Volume* 2007 Jan;89(1):33-8.
- (8) Saleh K, Olson M, Resig S, Bershady B, Kuskowski M, Gioe T, et al. Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. *Journal of Orthopaedic Research* 2002 May;20(3):506-15.
- (9) Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. *Ann Intern Med* 1997;127(5):380-7.
- (10) Gangireddy C, Rectenwald JR, Upchurch GR, Wakefield TW, Khuri S, Henderson WG, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. *J Vasc Surg* 2007 Feb;45(2):335-41.
- (11) Jones T, Ugalde V, Franks P, Zhou H, White RH. Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children. *Archives of Physical Medicine & Rehabilitation* 2005 Dec;86(12):2240-7.

- (12) Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. *Annals of Surgery* 2004 Aug;240(3):490-6.
- (13) Jun ZJ, Ping T, Lei Y, Li L, Ming SY, Jing W. Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. *Clinical & Laboratory Haematology* 2006 Apr;28(2):111-6.
- (14) Wahlander K, Larson G, Lindahl TL, Andersson C, Frison L, Gustafsson D, et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. *Thrombosis & Haemostasis* 2002 Apr;87(4):580-5.
- (15) Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement.[see comment][erratum appears in *JAMA* 1995 Jan 25;273(4):288]. *JAMA* 1994 Jun 8;271(22):1780-5.
- (16) Fitzgerald RH, Jr., Spiro TE, Trowbridge AA, Gardiner GA, Jr., Whitsett TL, O'Connell MB, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.[see comment]. *Journal of Bone & Joint Surgery - American Volume* 2001 Jun;83-A(6):900-6.
- (17) Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.[see comment]. *Archives of Internal Medicine* 2000 Jul 24;160(14):2199-207.
- (18) Turpie AG, Bauer KA, Eriksson BI, Lassen MR, Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.[see comment][erratum appears in *Lancet* 2002 Oct 5;360(9339):1102] 301. *Lancet* 2002 May 18;359(9319):1721-6.
- (19) Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.[see comment]. *Lancet* 2002 May 18;359(9319):1715-20.
- (20) Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.[see comment]. *Journal of Bone & Joint Surgery - British Volume* 1999 Jul;81(4):654-9.

- (21) Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. *Journal of Bone & Joint Surgery - British Volume* 2004 Jul;86(5):639-42.
- (22) Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement.[see comment]. *Journal of Bone & Joint Surgery - British Volume* 2002 Apr;84(3):344-50.
- (23) Welsby IJ, Podgoreanu MV, Phillips-Bute B, Mathew JP, Smith PK, Newman MF, et al. Genetic factors contribute to bleeding after cardiac surgery. *Journal of Thrombosis & Haemostasis* 2005 Jun;3(6):1206-12.
- (24) Segal JB, Streiff MB, Hoffman LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline.[summary for patients in *Ann Intern Med.* 2007 Feb 6;146(3):143; PMID: 17261855]. [Review] [122 refs]. *Annals of Internal Medicine* 2007 Feb 6;146(3):211-22.
- (25) Salvati EA, Pellegrini VD, Jr., Sharrock NE, Lotke PA, Murray DW, Potter H, et al. Recent advances in venous thromboembolic prophylaxis during and after total hip replacement.[see comment]. [Review] [131 refs]. *Journal of Bone & Joint Surgery - American Volume* 2000 Feb;82(2):252-70.
- (26) Sharrock NE, Go G, Harpel PC, Ranawat CS, Sculco TP, Salvati EA. The John Charnley Award. Thrombogenesis during total hip arthroplasty. *Clinical Orthopaedics & Related Research* 1995 Oct;(319):16-27.
- (27) Hooker JA, Lachiewicz PF, Kelley SS. Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty. *Journal of Bone & Joint Surgery - American Volume* 1999 May;81(5):690-6.
- (28) Lachiewicz PF, Soileau ES. Multimodal prophylaxis for THA with mechanical compression. *Clinical Orthopaedics & Related Research* 2006;453:225-30.
- (29) Woolson ST. Intermittent pneumatic compression prophylaxis for proximal deep venous thrombosis after total hip replacement.[see comment]. *Journal of Bone & Joint Surgery - American Volume* 1996 Nov;78(11):1735-40.
- (30) Ryan MG, Westrich GH, Potter HG, Sharrock N, Maun LM, Macaulay W, et al. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography.[see comment]. *Journal of Bone & Joint Surgery - American Volume* 2002 Nov;84-A(11):1998-2004.
- (31) Westrich GH, Specht LM, Sharrock NE, Sculco TP, Salvati EA, Pellicci PM, et al. Pneumatic compression hemodynamics in total hip arthroplasty. *Clinical Orthopaedics & Related Research* 2000 Mar;(372):180-91.

- (32) Lachiewicz PF, Kelley SS, Haden LR. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. A prospective, randomised study. *Journal of Bone & Joint Surgery - British Volume* 2004 Nov;86(8):1137-41.
- (33) Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. *Clinical Orthopaedics & Related Research* 2006;452:175-80.
- (34) Silbersack Y, Taute BM, Hein W, Podhaisky H. Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression. *Journal of Bone & Joint Surgery - British Volume* 2004 Aug;86(6):809-12.
- (35) Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. *Journal of Arthroplasty* 2006 Sep;21(6Suppl 2):139-43.
- (36) Lieberman JR, Huo MM, Hanway J, Salvati EA, Sculco TP, Sharrock NE. The prevalence of deep venous thrombosis after total hip arthroplasty with hypotensive epidural anesthesia. *Journal of Bone & Joint Surgery - American Volume* 1994 Mar;76(3):341-8.
- (37) Prins MH, Hirsh J. A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. [Review] [36 refs]. *Thrombosis & Haemostasis* 1990 Dec 28;64(4):497-500.
- (38) Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. [Review] [271 refs]. *Chest* 2004 Sep;126(3 Suppl):287S-310S.
- (39) Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. *Journal of Bone & Joint Surgery - British Volume* 2006 Mar;88(3):386-91.
- (40) Johnson R, Green JR, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. *Clinical Orthopaedics & Related Research* 1977;(127):123-32.
- (41) Phillips CB, Barrett JA, Losina E, Mahomed NN, Lingard EA, Guadagnoli E, et al. Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement.[see comment]. *Journal of Bone & Joint Surgery - American Volume* 2003 Jan;85-A(1):20-6.
- (42) Williams O, Fitzpatrick R, Hajat S, Reeves BC, Stimpson A, Morris RW, et al. Mortality, morbidity, and 1-year outcomes of primary elective total hip arthroplasty. *Journal of Arthroplasty* 2002 Feb;17(2):165-71.
- (43) Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip

or knee replacement. A randomized, double-blind, placebo-controlled trial.[see comment]. *Annals of Internal Medicine* 2000 Jun 6;132(11):853-61.

- (44) Colwell CW, Jr., Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.[see comment]. *Journal of Bone & Joint Surgery - American Volume* 1999 Jul;81(7):932-40.
- (45) Francis CW, Pellegrini VD, Jr., Totterman S, Boyd AD, Jr., Marder VJ, Liebert KM, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. *Journal of Bone & Joint Surgery - American Volume* 1997 Sep;79(9):1365-72.
- (46) Freedman KB, Brookenthal KR, Fitzgerald RH, Jr., Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. *Journal of Bone & Joint Surgery - American Volume* 2000 Jul;82-A(7):929-38.
- (47) Dalldorf PG, Perkins FM, Totterman S, Pellegrini VD, Jr. Deep venous thrombosis following total hip arthroplasty. Effects of prolonged postoperative epidural anesthesia.[see comment]. *Journal of Arthroplasty* 1994 Dec;9(6):611-6.
- (48) Pellegrini VD, Donaldson CT, Farber DC, Lehman EB, McCollister Evarts C. Prevention of Readmission for Venous Thromboembolism after Total Knee Arthroplasty. *Clinical Orthopaedics & Related Research* 2006;452:21-7.
- (49) Pellegrini VD, Jr., Donaldson CT, Farber DC, Lehman EB, Evarts CM. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. *Clinical Orthopaedics & Related Research* 2005 Dec;441:56-62.

## Appendices

### Appendix I: Systematic Review and Meta-Analysis Methods

#### Key Questions

The guideline recommendations are based on the answers to four Key Questions. These questions were specified prior to conducting the literature searches and frame the scope of the guideline. Questions were constructed to specify the patients, interventions, comparisons, and outcomes of interest. The Key Questions addressed by these guidelines were:

- 1A. In patients having knee replacement surgery, what is the effect of prophylactic therapy (e.g., coumadin, low molecular weight heparin, aspirin, mechanical devices) compared with either no prophylaxis or placebo in preventing important clinical symptoms or events (e.g., shortness-of-breath, chest pain, arrhythmia, fatality, rehospitalization) secondary to pulmonary embolism?
- 1B. In patients having hip replacement surgery, what is the effect of prophylactic therapy (e.g., coumadin, low molecular weight heparin, aspirin, mechanical devices) compared with either no prophylaxis or placebo in preventing important clinical symptoms or events (e.g., shortness-of-breath, chest pain, arrhythmia, fatality, rehospitalization) secondary to pulmonary embolism?
- 2A. In studies of knee replacement surgery, how do these different prophylactic therapies compare among each other in preventing important clinical symptoms or events secondary to pulmonary embolism?
- 2B. In studies of hip replacement surgery, how do these different prophylactic therapies compare among each other in preventing important clinical symptoms or events secondary to pulmonary embolism?
3. What are risks of clinically important adverse events associated with these prophylactic therapies in patients having knee or hip replacement surgery?
- 4A. What is the risk of important clinical symptoms or events secondary to pulmonary embolism in patients who had knee replacement surgery, in whom no prophylactic therapies for the prevention of pulmonary embolism were prescribed?
- 4B. What is the risk of important clinical symptoms or events secondary to pulmonary embolism in patients who had hip replacement surgery, in whom no prophylactic therapies for the prevention of pulmonary embolism were prescribed?

#### Literature Searches

We searched Medline from 1970 through August 2006 to identify all citations relevant for the guideline and the associated performance measures. Search terms included arthroplasty, replacement, knee prosthesis, hip prosthesis, and specific terms for anticoagulants, and mechanical intervention. The search strategies are provided (see Appendix Table 1). Additional articles, including later publications, were suggested by the Work Group members. These articles were screened in accordance with the same criteria as those found by the Medline search.

#### Appendix Table 1. MEDLINE search, August 28, 2006

#	Search History	Results
1	exp Arthroplasty, Replacement, Knee/ or exp Arthroplasty, Replacement, Hip/	10112
2	exp Hip Prosthesis/	13279























































